One important consideration is that our studies aimed at short-term outcomes, particularly subjective improvement in symptoms but future trials should aim to evaluate long-term outcomes including functional status, safety, pro-BNP changes and clinical endpoint (stroke, hospitalization) in a more diverse and representative population. The gene discussed is NPPB; the disease is stroke disorder.